Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.7.1.21 (thymidine kinase)
 7,561 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The in vivo toxic actions of cis-dichloro-1, 1-cyclo-butane-dicarboxylate platinum (II): carboplatin (CBDCA), cis-diisopropyl-ammine-transdihydroxy-dichloro platinum (IV) and iproplatin (CHIP) were compared with those of cis-diamminedichloroplatinum (II): cisplatin (CDDP) on rat bone marrow. To elucidate the biochemical basis of side effects of platinum analogs, the protein and DNA content, thymidine kinase (TK) EC 2.7.1.21 activity and cellularity (MNC) were measured from the femoral bone marrow at 48 hours after i.v. single injection of these three compounds using equitoxic doses as fraction of LD50 (CDDP: 9, CHIP: 50, CBDCA: 80 mg/kg). Dose response studies showed that each drug depressed in dose dependent fashion the cellularity, DNA content and TK activity. As the I50 values indicated, the CHIP caused the most toxic effect in the bone marrow and the influence of CBDCA was the least. The nadir of biochemical alterations was observed 24-48 hours after drug administration. The recovery of bone marrow was completed 96 hours after the treatment.
 ...
PMID:Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow. 251 64

The biochemical background of the intestinal side effects of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) and cis-diisopropylamine-trans-dihydroxy-dichloro platinum (IV) (CHIP) was compared with those of cis-diamminedichloroplatinum (II) (CDDP). Biochemical investigations were carried out on mucosal cells isolated by a combined chemical-mechanical method from the total length of the small intestine. After treatment with single, equitoxic doses of Pt analogues, the activities of thymidine kinase (TK) EC 2.7.1.21, sucrase (SUC) EC 3.2.1.26, maltase (MAL) EC 3.2.1.20, and protein content showed dose-dependent decreases, whereas the activity of alkaline phosphatase (AP) EC 3.2.1.20 increased slightly. The nadir of enzyme activity changes occurred 24-48 h after treatment. For the regeneration of the mucosa more than 96 h was necessary. Of the platinum analogues studied, CHIP proved to be the most toxic to the small intestine. While the highest doses of CDDP and CBDCA (0.66 x LD50) caused significant but less than 50% decreases in TK, SUC, MAL, and protein content (PROT), the CHIP doses needed for 50% reduction were between 0.44-0.66 x LD50.
 ...
PMID:Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP). 327 33